Lv1
46 积分 2023-10-10 加入
Synergy Between second-generation FLT3 inhibitors and the ERK1/2 inhibitor Ulixertinib in FLT3-ITD-mutated acute myeloid leukemia (AML) cells
1小时前
已完结
Pharmacomicrobiomics: The role of the gut microbiome in immunomodulation and cancer therapy
3个月前
已完结
Fighting the invisible foe in cancer therapy
9个月前
已完结
Intratumoral microbiome promotes liver metastasis and dampens adjuvant imatinib treatment in gastrointestinal stromal tumor
9个月前
已完结
Integrated microbiome and metabolome analysis reveals synergistic efficacy of basil polysaccharide and gefitinib in lung cancer through modulation of gut microbiota and fecal metabolites
9个月前
已完结
Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects
9个月前
已完结
Gut Microbiota and Liver Injury (I)—Acute Liver Injury
1年前
已关闭
Melatonin mitigates aflatoxin B1‐induced liver injury via modulation of gut microbiota/intestinal FXR/liver TLR4 signaling axis in mice
1年前
已完结
Contribution of gut microbiota to drug-induced liver injury
1年前
已完结
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
1年前
已完结
皖公网安备34019202002308
